Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

• Revenue in USD (TTM)0.00
• Net income in USD-42.47m
• Incorporated2006
• Employees26.00

• Location
  Protara Therapeutics Inc345 Park Avenue South, 3Rd FloorNEW YORK 10010United StatesUSA
• Phone+1 (646) 844-0337
• Fax+1 (302) 655-5049
• Websitehttps://protaratx.com/